<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6951</article-id>
      <article-id pub-id-type="doi">10.51847/aoLcKzpo1A</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Agentic Drug Discovery Requires a Scientific Constitution for Autonomous Planning, Tool Selection, Experimentation, and Human Intervention</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>O&#039;Donnell</surname>
                <given-names>Michael</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Byrne</surname>
                <given-names>Emma</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>O&#039;Connor</surname>
                <given-names>Nora</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Kelly</surname>
                <given-names>Aisling</given-names>
              </name>
                              <xref rid="aff4" ref-type="aff">4</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Agentic Drug Discovery and Scientific Constitution, Faculty of Pharmacy, University of Limerick, Limerick, Ireland.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Autonomous Planning and Tool Selection, Faculty of Pharmaceutical Sciences, University College Cork, Cork, Ireland.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Experimentation and Human Intervention, School of Pharmacy, University College Dublin, Dublin, Ireland.
          </aff>
                  <aff id="aff4">
            <label>4</label>Department of Agentic AI Governance in Drug Discovery, Faculty of Pharmacy, University of Galway, Galway, Ireland.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>28</day>
        <month>10</month>
        <year>2025</year>
      </pub-date>
      <volume>16</volume>
      <issue>5</issue>
      <fpage>99</fpage>
      <lpage>108</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Artificial intelligence in drug discovery is moving from bounded prediction toward systems that can formulate plans, select computational and laboratory tools, revise strategies, and initiate experiments. This transition changes the scientific governance problem because an agent may influence not only what is predicted but also which evidence is gathered, which hypotheses are pursued, and which physical actions are undertaken. Conventional evaluation based on predictive accuracy, task completion, or benchmark performance cannot determine whether such agency is scientifically justified, appropriately bounded, reproducible, or accountable. This article develops a proposed scientific constitution for agentic drug discovery. The constitution is conceived as a structured allocation of scientific authority, evidence requirements, permissions, prohibitions, challenge rights, escalation conditions, and human intervention powers. It distinguishes scientific roles from technical capabilities, tool availability from tool suitability, model confidence from calibrated uncertainty, molecular plausibility from experimental confirmation, and successful task execution from pharmaceutical usefulness. The proposed construct connects four governance layers: role-bound authority, evidence warrants, rules for planning and action, and accountability through logging, challenge, override, and explicit reauthorization. It further argues that autonomous experimentation should be governed through consequence-sensitive permissions rather than a binary distinction between autonomous and non-autonomous systems. The contribution is theoretical and has not been empirically validated, standardized, or demonstrated to ensure safe deployment. Its applicability will depend on the task, laboratory environment, evidence maturity, chemical hazards, institutional responsibilities, and effectiveness of human oversight. The scientific constitution is therefore offered as an organizing framework for designing and evaluating bounded agency, not as a regulatory instrument or authorization for operational autonomy.</p>
      </abstract>
      <kwd-group>
                <kwd>Agentic artificial intelligence</kwd>
                <kwd>Autonomous drug discovery</kwd>
                <kwd>Scientific governance</kwd>
                <kwd>Tool-using agents</kwd>
                <kwd>Self-driving laboratories</kwd>
                <kwd>Human oversight</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>